ChemoCentryx

CCXI NASDAQ
8.78
+0.44
+5.28%
Closed 16:25 06/17 EDT
Open
8.67
Prev Close
8.34
High
8.88
Low
8.45
Volume
318.47K
Avg Vol (3M)
578.19K
52 Week High
14.98
52 Week Low
8.06
% Turnover
0.55%
Market Cap
509.66M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers ChemoCentryx CCXI stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).
MORE >

Recently

Name
Price
%Change